IGC Receives No objection letter from Health Canada JAN 4. 3023 January 17, 2023January 19, 2023 by Alejandro
IGC Applauds Signing of Bipartisan Medical Marijuana and Cannabidiol Research Expansion Act December 7, 2022 by shivam singh
IGC Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC-AD1 for the Treatment of Agitation in Dementia From Alzheimer’s Disease December 1, 2022December 1, 2022 by Alejandro
IGC to Present at the RHK 2022 Disruptive Growth Conference November 30, 2022November 30, 2022 by Alejandro
IGC Reports Financial Results for the Quarter Ended September 30, 2022 November 1, 2022November 1, 2022 by Alejandro
IGC Announces Issuance of Second Patent for the Treatment of Alzheimer’s Using THC September 21, 2022 by Alejandro
IGC Reports Financial Results for the Quarter Ended June 30, 2022 August 8, 2022August 8, 2022 by Alejandro
IGC Reports Financial Results for Fiscal Year Ended March 31, 2022 June 23, 2022June 23, 2022 by Alejandro
IGC Acquires Exclusive Rights for a Potential Alzheimer’sDrug Development Candidate June 21, 2022June 21, 2022 by Alejandro
IGC Receives U.S. Patent for Method and Composition for Treating Seizure Disorders June 9, 2022June 9, 2022 by Alejandro
India Globalization Capital, Inc. (IGC) Announces Final Approval of Settlement of Shareholder Class Action Lawsuits April 18, 2022April 18, 2022 by Alejandro
